This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo
by Zacks Equity Research
BioCryst (BCRX) obtains FDA approval for berotralstat for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients.
Rhythm (RYTM) Up on FDA Approval of Weight Management Drug
by Zacks Equity Research
Rhythm's (RYTM) stock gains as FDA approves its lead product candidate for chronic weight management.
Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval
by Zacks Equity Research
Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.
Roche (RHHBY) Gets FDA Nod for Influenza Drug Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for Xofluza to prevent influenza in people 12 years of age and older following contact with someone with influenza.
Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed
by Zacks Equity Research
Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.
Roche's (RHHBY) Influenza Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Roche's (RHHBY) influenza drug Xofluza and Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) get a positive CHMP opinion.
Vanda Pharmaceuticals (VNDA) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 37.50% and -5.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and -1.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
by Zacks Equity Research
Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.
Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Apr 17, 2020
by Zacks Equity Research
Companies in the news are: TSM, BK, LOVE, VNDA
Vanda Begins Enrollment in Study for Severe Coronavirus Infection
by Zacks Equity Research
Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.
7 Stocks With Low Price-to-Sales Ratio for a Solid Portfolio
by Zacks Equity Research
A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Value Stocks to Buy for November 14th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 14th
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study
by Zacks Equity Research
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder.
Why Vanda (VNDA) Might be Well Poised for a Surge
by Zacks Equity Research
Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Vanda Pharmaceuticals (VNDA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 800.00% and 7.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vanda Pharmaceuticals (VNDA) Q1 Earnings Top Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 500.00% and -7.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?